Cargando…
Interpretation of Serological Complement Biomarkers in Disease
Complement system aberrations have been identified as pathophysiological mechanisms in a number of diseases and pathological conditions either directly or indirectly. Examples of such conditions include infections, inflammation, autoimmune disease, as well as allogeneic and xenogenic transplantation...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207586/ https://www.ncbi.nlm.nih.gov/pubmed/30405598 http://dx.doi.org/10.3389/fimmu.2018.02237 |
_version_ | 1783366537224126464 |
---|---|
author | Ekdahl, Kristina N. Persson, Barbro Mohlin, Camilla Sandholm, Kerstin Skattum, Lillemor Nilsson, Bo |
author_facet | Ekdahl, Kristina N. Persson, Barbro Mohlin, Camilla Sandholm, Kerstin Skattum, Lillemor Nilsson, Bo |
author_sort | Ekdahl, Kristina N. |
collection | PubMed |
description | Complement system aberrations have been identified as pathophysiological mechanisms in a number of diseases and pathological conditions either directly or indirectly. Examples of such conditions include infections, inflammation, autoimmune disease, as well as allogeneic and xenogenic transplantation. Both prospective and retrospective studies have demonstrated significant complement-related differences between patient groups and controls. However, due to the low degree of specificity and sensitivity of some of the assays used, it is not always possible to make predictions regarding the complement status of individual patients. Today, there are three main indications for determination of a patient's complement status: (1) complement deficiencies (acquired or inherited); (2) disorders with aberrant complement activation; and (3) C1 inhibitor deficiencies (acquired or inherited). An additional indication is to monitor patients on complement-regulating drugs, an indication which may be expected to increase in the near future since there is now a number of such drugs either under development, already in clinical trials or in clinical use. Available techniques to study complement include quantification of: (1) individual components; (2) activation products, (3) function, and (4) autoantibodies to complement proteins. In this review, we summarize the appropriate indications, techniques, and interpretations of basic serological complement analyses, exemplified by a number of clinical disorders. |
format | Online Article Text |
id | pubmed-6207586 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-62075862018-11-07 Interpretation of Serological Complement Biomarkers in Disease Ekdahl, Kristina N. Persson, Barbro Mohlin, Camilla Sandholm, Kerstin Skattum, Lillemor Nilsson, Bo Front Immunol Immunology Complement system aberrations have been identified as pathophysiological mechanisms in a number of diseases and pathological conditions either directly or indirectly. Examples of such conditions include infections, inflammation, autoimmune disease, as well as allogeneic and xenogenic transplantation. Both prospective and retrospective studies have demonstrated significant complement-related differences between patient groups and controls. However, due to the low degree of specificity and sensitivity of some of the assays used, it is not always possible to make predictions regarding the complement status of individual patients. Today, there are three main indications for determination of a patient's complement status: (1) complement deficiencies (acquired or inherited); (2) disorders with aberrant complement activation; and (3) C1 inhibitor deficiencies (acquired or inherited). An additional indication is to monitor patients on complement-regulating drugs, an indication which may be expected to increase in the near future since there is now a number of such drugs either under development, already in clinical trials or in clinical use. Available techniques to study complement include quantification of: (1) individual components; (2) activation products, (3) function, and (4) autoantibodies to complement proteins. In this review, we summarize the appropriate indications, techniques, and interpretations of basic serological complement analyses, exemplified by a number of clinical disorders. Frontiers Media S.A. 2018-10-24 /pmc/articles/PMC6207586/ /pubmed/30405598 http://dx.doi.org/10.3389/fimmu.2018.02237 Text en Copyright © 2018 Ekdahl, Persson, Mohlin, Sandholm, Skattum and Nilsson. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Ekdahl, Kristina N. Persson, Barbro Mohlin, Camilla Sandholm, Kerstin Skattum, Lillemor Nilsson, Bo Interpretation of Serological Complement Biomarkers in Disease |
title | Interpretation of Serological Complement Biomarkers in Disease |
title_full | Interpretation of Serological Complement Biomarkers in Disease |
title_fullStr | Interpretation of Serological Complement Biomarkers in Disease |
title_full_unstemmed | Interpretation of Serological Complement Biomarkers in Disease |
title_short | Interpretation of Serological Complement Biomarkers in Disease |
title_sort | interpretation of serological complement biomarkers in disease |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207586/ https://www.ncbi.nlm.nih.gov/pubmed/30405598 http://dx.doi.org/10.3389/fimmu.2018.02237 |
work_keys_str_mv | AT ekdahlkristinan interpretationofserologicalcomplementbiomarkersindisease AT perssonbarbro interpretationofserologicalcomplementbiomarkersindisease AT mohlincamilla interpretationofserologicalcomplementbiomarkersindisease AT sandholmkerstin interpretationofserologicalcomplementbiomarkersindisease AT skattumlillemor interpretationofserologicalcomplementbiomarkersindisease AT nilssonbo interpretationofserologicalcomplementbiomarkersindisease |